Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026

What happened: Cellectis presented expanded preclinical data at ESGCT 2026 for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, delivered as mRNA in liver-directed lipid nanoparticles. Key numbers: About 90% mean APOC3 editing in vitro; about 65% mean in vivo editing, up to 70%; APOC3 reduced 67% ± 12% and triglycerides 75% ± 11% in a Why it matters: Cellectis said the data reinforce the potential of its TALE base editing approach and support development of .HEAL-101 as a potential one-time treatment for severe hypertriglyceridemia.

Cellectis presented expanded preclinical data at ESGCT 2026 for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, delivered as mRNA in liver-directed lipid nanoparticles.

Cellectis said the data reinforce the potential of its TALE base editing approach and support development of .HEAL-101 as a potential one-time treatment for severe hypertriglyceridemia.